ANASTROZOLE- anastrozole tablets tablet

However, sometimes it’s used off-label to prevent breast cancer in certain women who are at high risk for the condition. Arimidex for breast cancer Arimidex is FDA-approved to treat breast cancer in women who’ve gone through menopause. Clinical studies steroid shop legit of Arimidex followed women with early breast cancer who took the drug for 5 years. And the studies were continued for an additional 5 years after the women stopped taking the drug. No new side effects were reported during this additional time.

A dose-related increasewas observed in the incidence of ovarian and uterine hyperplasia in females. A dose-related increase in theincidence of ovarian hyperplasia was also observed in female mice. Theseovarian changes are considered to be rodent-specific effects of aromatase inhibition and are of questionable significance to humans. The incidence oflymphosarcoma was increased in males and females at the high dose.

• Avoid storing this medication in areas where it could get damp or wet, such as in bathrooms.
• ARIMIDEX is indicated for thefirst-line treatment of postmenopausal women with hormone receptor-positive orhormone receptor unknown locally advanced or metastatic breast cancer.
• And there is not enough information available to say if it’s safe.
• Do not give ARIMIDEX to otherpeople, even if they have the same symptoms that you have.

Bisphosphonate treatment preserved bone density in most patients at risk of fracture. The primary endpoint of the trial was disease-freesurvival (i.e., time to occurrence of a distant or local recurrence, or contralateral breast cancer or death from any cause). Secondary endpoints ofthe trial included distant disease-free survival, the incidence ofcontralateral breast cancer and overall survival. At a median follow-up of 33months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacybenefit when compared with tamoxifen in all patients as well as in the hormonereceptor positive subpopulation.

Please verify you are a human

However, much of the information may also apply to unapproved uses that are being studied. DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X. Patients should be informed that an increased level of cholesterol might be seen while receiving Anastrozole. BThe proportion of patients with 120 months’ follow-up was 29.8%.

Report Problems to the Food and Drug Administration

With early breast cancer, the cancer hasn’t spread out of either your breast or the lymph nodes in your armpit. But with advanced breast cancer, the cancer has either spread to nearby areas or lymph nodes (called locally advanced breast cancer) or spread to other parts of your body (called metastatic breast cancer). For the side effects described below, results from clinical studies of women with either early breast cancer or advanced breast cancer are shown. Inhibition of aromatase activity is primarily due toanastrozole, the parent drug.

Access medical and health information

They can also calculate how well anastrozole is likely to work for you. This is done by comparing your details with those of more than 20,000 other people who have had treatment for breast cancer. Anastrozole belongs to a group of medicines called aromatase inhibitors. If you’re sexually active and you or your partner can become pregnant, talk with your doctor about your birth control needs while you’re using Arimidex. If you drink alcohol and you’re concerned about how this could affect your breast cancer or its treatment, talk with your doctor.

In animal studies, anastrozole caused pregnancy failure, increasedpregnancy loss, and signs of delayed fetal development. If ARIMIDEX is used during pregnancy, or if thepatient becomes pregnant while receiving this drug, the patient should be apprisedof the potential hazard to the fetus and potential risk for pregnancy loss. ARIMIDEX is indicated for thefirst-line treatment of postmenopausal women with hormone receptor-positive orhormone receptor unknown locally advanced or metastatic breast cancer. Both trials included over 375 patients; demographics and other baseline characteristics were similar for the three treatment groups in each trial. Patients in the 0005 trial had responded better to prior tamoxifen treatment. In Trial 0004, 81% of patients were ER-positive, 13% were ER-unknown, and 6% were ER-negative.